Eli Lilly slides 6% on rare Wall Street downgrade
HSBC cuts rating to sell citing overvaluation and intensifying competition in weight loss drug market
Eli Lilly shares tumbled 6.1% to $929.27 on Tuesday after HSBC analysts issued a rare downgrade, warning that the pharmaceutical giant's stock is "priced to perfection" amid intensifying competition in the lucrative weight loss drug market.
The $882bn market cap company received its only sell-equivalent rating on Wall Street as HSBC analyst Rajesh Kumar downgraded the stock to "reduce" from "hold" and slashed the price target to $850 from $1,070. The move stands in stark contrast to the consensus view of most analysts, who maintain a moderate buy rating with an average target of $1,217.
"On balance, we do not like the risk/reward balance in Lilly shares," HSBC analysts wrote in their note. The downgrade reflects concerns that Eli Lilly's spectacular rally—shares have nearly doubled over the past two years—has already priced in optimistic growth assumptions that may be difficult to achieve.
The timing of the bearish call is particularly noteworthy coming just six weeks after Eli Lilly reported fourth-quarter earnings that shattered analyst expectations. The company delivered 43% revenue growth to $19.3bn, driven by explosive demand for its GLP-1 weight loss treatments Mounjaro and Zepbound. Combined sales of the two drugs reached $11.7bn in the quarter, representing roughly 60% of total revenue.
However, HSBC argues that the obesity drug market's total addressable market has been overestimated by Wall Street. The firm projects the market will reach $80bn to $120bn by 2032, significantly below consensus estimates exceeding $150bn. HSBC cited what it views as inflated expectations for Eli Lilly's experimental oral obesity therapy orforglipron, noting concerns about patient compliance and persistence.
Price competition represents another growing headwind. The analyst anticipates increased pricing pressure within the GLP-1 market, with expected price cuts in 2026 that could squeeze margins. Eli Lilly's business model also shows greater reliance on the cash-pay channel compared to rival Novo Nordisk, a strategy that may prove more vulnerable to economic fluctuations.
The downgrade highlights growing tensions between Eli Lilly's fundamental strength and its premium valuation. The stock currently trades at 42.9 times trailing earnings, well above the pharmaceutical industry average despite its superior growth profile. Even using forward earnings estimates, the multiple remains elevated at 28.8 times.
Eli Lilly's dependence on its GLP-1 franchise has become increasingly pronounced. Mounjaro and Zepbound generated a combined $36.5bn in revenue during 2025, accounting for more than half of the company's $65.2bn in annual sales. While this concentration has powered extraordinary growth, it also creates concentration risk should competition intensify or market dynamics shift.
The company is attempting to diversify its pipeline, but HSBC remains skeptical about the trajectory of oral weight loss treatments that investors hope will unlock a broader patient population. The firm's concerns underscore the challenges Eli Lilly faces in maintaining its market leadership position against Novo Nordisk's competing offerings including Wegovy and Ozempic.
Despite Tuesday's sharp decline, Eli Lilly shares remain up substantially over the past year, having benefited from what many analysts view as a once-in-a-generation pharmaceutical opportunity in the obesity treatment market. The stock's 52-week high of $1,132, reached earlier this month, reflects investor enthusiasm for a company that has successfully pivoted from its traditional diabetes franchise to become a dominant player in the weight loss revolution.
HSBC's contrarian view may test the market's confidence in Eli Lilly's growth trajectory. As competition intensifies and pricing pressures mount, the pharmaceutical giant will need to demonstrate that its current valuation can be justified by sustained execution and continued innovation beyond its core GLP-1 franchise.